Randomized phase II/III study of adjuvant chemotherapy with Adriamycin+Ifosfamide vs Gemcitabine+Docetaxel for high-grade soft tissue sarcoma (JCOG1306, AI vs GD for STS RPII/III)
Phase 2
- Conditions
- soft tissue sarcoma
- Registration Number
- JPRN-UMIN000013175
- Lead Sponsor
- Japan Clinical Oncology Group (JCOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
1) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or intramucosal tumors curatively treated with local therapy 2) Active infection requiring systemic therapy 3) Body temperature >= 38 degrees Celsius 4) Women in pregnant, possibly pregnant or breast feeding 5) Psychiatric disease 6) Patients requiring systemic steroid medication 7) Unstable angina within 3 weeks, or with a history of myocardial infarction 8) Poorly controlled hypertension 9) Poorly controlled diabetes mellitus or routine administration of insulin 10) Positive HBs antigen
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method